



Ashley, actual Renvovi patient

Revcovi[®] (elapegademase-lvlr) Getting Started Guide

To get a patient started on Renvovi[®] (elapegademase-lvlr) follow **2 steps** outlined in this guide.

Revcovi

Visit chiesitotalcare.com or
call 1-866-272-7078 – we're ready to help!

INDICATION

Revcovi[®] (elapegademase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- Injection site bleeding in patients with thrombocytopenia: Increased risk of local bleeding in patients with thrombocytopenia; should not be used if thrombocytopenia is severe.
- Delay in improvement of immune function: Protect immune deficient patients from infections until improvement in immune function.

ADVERSE REACTIONS

The most commonly reported adverse reactions were cough (50%) and vomiting (33%).

In addition, the following post-marketing reports for the same class of enzyme replacement therapy used in the treatment of ADA-SCID may also be seen with Renvovi treatment:

- Hematologic events: hemolytic anemia, autoimmune hemolytic anemia, thrombocythemia, thrombocytopenia and autoimmune thrombocytopenia
- Dermatological events: injection site erythema, urticaria
- Lymphomas

IMPORTANT MONITORING INFORMATION

Treatment with Renvovi should be monitored by measuring trough plasma ADA activity and trough dAXP levels for maintenance of therapeutic targets. If a persistent decline in plasma ADA activity occurs, immune function and clinical status should be monitored closely, and precautions should be taken to minimize the risk of infection.

Please see Important Safety Information throughout and accompanying full Prescribing Information.

A

Specify appropriate ICD-10 Diagnosis code(s) for secondary diagnosis

(Other uses are at prescriber's discretion)

ICD-10 Diagnosis Codes	
Diagnosis	Current indication
D81.3	Adenosine deaminase deficiency, unspecified
D81.31	Severe combined immunodeficiency due to adenosine deaminase deficiency
D81.9	Combined immunodeficiency, unspecified

Intended as a reference for coding and billing for product and associated services. Not intended to be a directive, nor does the use of the recommended codes guarantee reimbursement. Providers are responsible for ensuring the accuracy and validity of all billing and claims for appropriate reimbursement.

B

Recommended starting dose



0.4 mg/kg/wk based on ideal body weight or actual weight, whichever is greater



Divided into 2 weekly doses for a minimum of 12-24 weeks



Until immune reconstitution is achieved

- Once immune reconstitution is achieved, dose may be gradually adjusted down to maintain trough ADA activity >30 mmol/hr/L, trough dAXP levels <0.02 mmol/L, and/or to maintain adequate immune reconstitution based on the clinical assessment of the patient
- Improvement in the general clinical status of the patient may be gradual but should be apparent by the end of the first year of therapy

Refer to administration guide for details.

Sample dosing assuming 60 kg patient @ 0.4 mg/kg/wk

Instructions: Inject 12 mg
Intramuscularly (IM) 2 times per week.

C

Ask each patient to sign the Patient Consent Form



Please ask each patient to sign the Patient Consent Form before they leave the office and fax it along with the Enrollment form for each patient. Participation in the Chiesi Total Care program is optional.

Step 2:

Once you have completed the form:



Ashley, actual Revcovii patient

1. Attach copies of patient insurance and prescription cards – front and back.

2. First prescription for the patient:

The first copy of the form must be faxed for each patient. Fax completed form to Chiesi Total CareSM at 1-866-272-7079. **Please complete one form per patient.**

3. Subsequent prescriptions:

If you wish to send additional forms via e-script please search for “Eversana Life Science Services” in your EMR/HMR’s e-prescribing software.



Scan to submit online RX form




Scan to download RX form

Visit chiesitotalcare.com
or call 1-866-272-7078.
We're ready to help!

Chiesi Total CareSM is a comprehensive support program that provides service to patients and healthcare providers.

A single call to your dedicated Chiesi Total Care team is all it takes, and they will guide you through the process of getting a patient started on Revcovi therapy.

Ashley, actual
Revcovi patient



INDICATION

Revcovi[®] (elapegamase-lvlr) is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- Injection site bleeding in patients with thrombocytopenia: Increased risk of local bleeding in patients with thrombocytopenia; should not be used if thrombocytopenia is severe.
- Delay in improvement of immune function: Protect immune deficient patients from infections until improvement in immune function.

ADVERSE REACTIONS

The most commonly reported adverse reactions were cough (50%) and vomiting (33%).

In addition, the following post-marketing reports for the same class of enzyme replacement therapy used in the treatment of ADA-SCID may also be seen with Revcovi treatment:

- Hematologic events: hemolytic anemia, autoimmune hemolytic anemia, thrombocytopenia, thrombocytopenia and autoimmune thrombocytopenia
- Dermatological events: injection site erythema, urticaria
- Lymphomas

IMPORTANT MONITORING INFORMATION

Treatment with Revcovi should be monitored by measuring trough plasma ADA activity and trough dAXP levels for maintenance of therapeutic targets. If a persistent decline in plasma ADA activity occurs, immune function and clinical status should be monitored closely, and precautions should be taken to minimize the risk of infection.

Please see Important Safety Information throughout and accompanying full Prescribing Information.

References: 1. Revcovi[®] (elapegamase-lvlr) Prescribing Information. Chiesi USA, Inc.; 2020.

For more information, visit revcovi.com.

Chiesi Total CareSM Program offered through EVERSANA Life Science Services Specialty Pharmacy

©Chiesi USA, Inc. 2025. All rights reserved.

Revcovi[®] is a registered trademark owned by Unikeris Ltd.

Chiesi Total CareSM is a service mark owned by Chiesi Farmaceutici S.p.A.

All other trademarks are the property of their respective owners.

PP-RV-0101 V2.0

Revcovi